The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds

• Nanda Kumar Sasi,

  Affiliations Laboratory of Genome Integrity and Tumorigenesis, Van Andel Research Institute (VARI), Grand Rapids, MI, United States of America, Graduate Program in Genetics, Michigan State University, East Lansing, MI, United States of America

  ⨯
• Kanchan Tiwari,

  Affiliation Laboratory of Genome Integrity and Tumorigenesis, Van Andel Research Institute (VARI), Grand Rapids, MI, United States of America

  ⨯
• Fen-Fen Soon,

  Affiliation Laboratory of Structural Sciences, VARI, Grand Rapids, MI, United States of America

  ⨯
• Dorine Bonte,

  Current address: Centre National de la Recherche Scientifique, Institut Gustave Roussy, Villejuif, France, and Université Paris Sud, Orsay, France

  Affiliation Laboratory of Genome Integrity and Tumorigenesis, Van Andel Research Institute (VARI), Grand Rapids, MI, United States of America

  ⨯
• Tong Wang,

  Affiliation Translational Drug Development, Inc. (TD2), Scottsdale, AZ, United States of America

  ⨯
• Karsten Melcher,

  Affiliation Laboratory of Structural Biology and Biochemistry, VARI, Grand Rapids, MI, United States of America

  ⨯
• H. Eric Xu,

  Affiliation Laboratory of Structural Sciences, VARI, Grand Rapids, MI, United States of America

  ⨯
• Michael Weinreich

  * E-mail: michael.weinreich@vai.org

  Affiliation Laboratory of Genome Integrity and Tumorigenesis, Van Andel Research Institute (VARI), Grand Rapids, MI, United States of America

  ⨯